Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study

NCT00431379 | Withdrawn Phase 1

• 1 other identifier: H0605329
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

The pathogenesis of ARDS appears to be from damage to the alveolar-capillary barrier, which is composed of the microvascular endothelium and the alveolar epithelium. This damage may occur from direct or indirect lung injury. The mechanism of injury to the alveolar capillary barrier appears to be through neutrophil-mediated injury, pro-inflammatory cytokines, ventilator-induced lung injury with alveolar over distention and abnormalities of the coagulation system. This results in blood clot formation in the microcirculation of the lung. Thrombolytics can dissolve blood clots and result in increased blood flow to the organs. This treatment may benefit ARDS patients, thus the purpose of this study. Hardaway, et al.studied the effects of thrombolytics on ARDS in pigs. The experimental group showed improved oxygenation and survival as compared to controls. There was no bleeding complications noted with this therapy. Dr. Hardaway followed this animal study with a phase I clinical trial involving 20 patients with ARDS. The patients were treated with IV streptokinase or urokinase. Nineteen of the 20 patients showed an increase in PA02 after thrombolytic therapy. There were no significant bleeding complications in patients that were critically ill on ventilators. We propose an additional phase I pilot study to evaluate the effectiveness and safety of Tenecteplase for the treatment of ARDS. Unlike the other fibrinolytics studied in this disease state, Tenecteplase, is more fibrin specific and has increased resistance to plasminogen activator inhibitor (PAI-I) at greater levels than other available fibrinolytics. We have chosen an experimental dose escalation trial design of tenecteplase that has demonstrated initial safety trends in a Phase I acute ischemic stroke trial. The initial dose is 0.1 mg/kg IV and will increase to 0.2 mg/kg, 0.3 mg/kg, with a final cohort of patients receiving 0.4 mg/kg. Drug administration will be a single dose bolus in each cohort. Advancement of dose will occur if safety is not in question in the previous cohort. We hope this will provide an acceptable benefit risk ratio as the mortality of ARDS is approximately 30 - 60%. All patients will be closely monitored for any change in clotting parameters and signs of bleeding. Tenecteplase will be administered via a peripheral IV as described in the package insert.

Conditions

Acute Respiratory Distress Syndrome

Outcome Measures

Primary Outcomes (2)

• Survival to Discharge

• Safety Analysis of Bleeding Complications

Secondary Outcomes (5)

• Improved Pa02/Fi02 ratio

• Improved cardiac profile

• Incidence of organ failure

• Decreased ventilator days

• Decreased ICU days

Interventions

Tenecteplase DRUG

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ability to provide written informed consent and comply with study assessments for full duration of the study by family member.

You may not qualify if:

• Disease-related considerations - ARDS is indicated by respiratory failure of acute onset, bilateral lung infiltrates, PaO2/Fi02 \<200 mmHg,pulmonary artery wedge pressure \< 18 mmHg, and need for a ventilator. (If the wedge pressure is \>18, the patient is excluded from this study).
• Only acute stage ARDS patients will be enrolled in the study. This is defined by patients with ARDS for \<1 week.
• Other considerations
• Satisfactory recruitment and cooperation
• A signed informed consent document
• No participation in another clinical and/or observational trial
• No previous participation in this study
• Not a prisoner or otherwise in custody and not institutionalized for mental incompetence.
• Patients with major trauma will only be included 5 days after trauma has occurred.
• Bleeding - active internal bleeding
• History of cerebrovascular accident
• Intracranial neoplasm, arteriovenous malformation, or aneurysm or acute trauma
• Known bleeding diathesis
• Severe uncontrolled HTN
• Thrombin time over 2 times laboratory normal

Sponsors & Collaborators

• Wake Forest University Health Sciences: lead
• Genentech, Inc.: collaborator

Study Sites (1)

Medical Center of Central GA

Macon, Georgia, 31201, United States

Location

MeSH Terms

Conditions

Respiratory Distress Syndrome

Interventions

Tenecteplase

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Respiration Disorders

Intervention Hierarchy (Ancestors)

Tissue Plasminogen Activator; Serine Endopeptidases; Endopeptidases; Peptide Hydrolases; Hydrolases; Enzymes; Enzymes and Coenzymes; Serine Proteases; Plasminogen Activators; Blood Coagulation Factors; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins

Study Officials

• Dennis W. Ashley, MD, FACS

  Medical Center of Central GA

  PRINCIPAL INVESTIGATOR

• Debra M Kitchens, RN, CEN

  Medical Center of Central Georgia

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 2, 2007
• First Posted: February 5, 2007
• Study Start: February 1, 2007
• Primary Completion: November 1, 2008
• Study Completion: December 1, 2008
• Last Updated: October 16, 2024

Record last verified: 2013-11

Locations

US (1)